Skip to main content

    Wedbush downgrades Compass Therapeutics (CMPX) to Neutral

    GNG Research Market News

    By GNG Research

    On September 23, 2026, Wedbush cut its Compass Therapeutics Inc. (CMPX) rating from Outperform to Neutral.

    Among five firms active over the past 90 days, four hold a bullish rating. 13 analysts set consensus price targets as of October 30, 2026, with a mean of $6.03, a median of $6.12 and a range of $1.01 to $12.60.

    Consensus Q4 FY2026 EPS is -$0.14, with revenue at $0. The next earnings report is on March 3, 2027.